Jagsonpal Pharmaceuticals Q3 FY26 results: revenue flat, 9M up around 6 percent
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited results for Q3 and nine months ended Dec 31, 2025. Q3 revenue from operations stood at Rs 729.45M, marginally lower than Rs 740.25M a year earlier. Nine-month revenue grew to Rs 2,230.22M from Rs 2,101.56M, up about 6 percent. Total income for 9M reached Rs 2,318.49M versus Rs 2,155.76M last year. Company booked an exceptional item of Rs 20.79M for one-time impact of the new Labour Codes. Auditor Walker Chandiok issued a clean limited review report. Company also allotted 150,016 shares under ESOP 2022 and plans to appeal a Rs 15.20M SGST demand order.
Flat quarter, steady 9M growth. One-time Labour Codes charge may pressure near-term margins. Clean auditor report, modest ESOP dilution.